Prediction of binding to MHC class I molecules.

[1]  G Hermanson,et al.  Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.

[2]  M F del Guercio,et al.  Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.

[3]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[4]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[5]  V. Engelhard.  Structure of peptides associated with MHC class I molecules. , 1994, Current opinion in immunology.

[6]  V. Engelhard,et al.  Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.

[7]  J Alexander,et al.  Antigen analogs/MHC complexes as specific T cell receptor antagonists. , 1994, Annual review of immunology.

[8]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[9]  F J Ayala,et al.  MHC polymorphism and human origins. , 1993, Scientific American.

[10]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[11]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[12]  R. Henderson,et al.  Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. , 1993, Journal of immunology.

[13]  D. Wraith,et al.  MHC binding peptides as therapeutic agents. , 1993, Clinical and experimental rheumatology.

[14]  L. Adorini.  Selective inhibition of T cell responses by protein and peptide-based immunotherapy. , 1993, Clinical and experimental rheumatology.

[15]  T. Whiteside,et al.  T cell recognition of human tumors: implications for molecular immunotherapy of cancer. , 1993, Clinical immunology and immunopathology.

[16]  H. Rammensee,et al.  Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. , 1992, International immunology.

[17]  Anders Krogh,et al.  Introduction to the theory of neural computation , 1994, The advanced book program.

[18]  Clifford Lau,et al.  Neural Networks: Theoretical Foundations and Analysis , 1991 .

[19]  W. Kast,et al.  Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus‐induced tumours and peptide‐mhc binding , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[20]  Alexander Linden,et al.  Inversion of neural networks by gradient descent , 1990, Parallel Comput..

[21]  J. Bodmer,et al.  Nomenclature for factors of the HLA system, 1987. , 1988, Tissue antigens.

[22]  Geoffrey E. Hinton,et al.  Learning representations by back-propagating errors , 1986, Nature.